Astrana Health (ASTH) experienced a sharp market reaction after its latest quarterly results revealed a significant miss in earnings per share, along with a lowered outlook for full-year financial guidance.
See our latest analysis for Astrana Health.
Astrana Health’s share price has been hit hard, falling 34% in the past week after the earnings miss and guidance cut rattled investors. The company’s stock had already been losing ground this year, and its total return of -48% over the past twelve months underscores that momentum has decisively faded despite revenue growth and occasional insider buying.
If this recent volatility has you thinking about new investment angles, now is a great moment to discover other healthcare stocks with attractive fundamentals. See the opportunities in our healthcare stock screener: See the full list for free.
With shares trading near multi-year lows and analyst price targets still far above current levels, the key question is whether Astrana Health is now an undervalued opportunity or if the market has fully priced in the company’s growth challenges.
Compared to Astrana Health’s last closing price of $21.91, the most closely watched narrative presents a much higher fair value, hinting at resilience beyond this quarter’s weakness.
Long-term tailwinds from regulatory and payer shifts towards alternative payment models and value-based healthcare are expanding the addressable market and favor operators with mature, risk-bearing platforms like Astrana, setting the stage for durable revenue and profit growth as national healthcare expenditure rises.
Want to know why this fair value nearly doubles the market price? The narrative’s foundation is big revenue growth and expanding profit margins, which together fuel a potentially sharp re-rating. Curious what assumptions drive this bullish outlook? You’ll need to uncover the projections yourself.
Result: Fair Value of $43.89 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, significant Medicaid exposure and challenges with integrating acquisitions could undermine Astrana’s outlook if policy shifts or operational hurdles arise.
Find out about the key risks to this Astrana Health narrative.
While analysts see Astrana Health as undervalued on a fair value basis, the current price-to-earnings ratio tells a different story. At 115.2x, it is much higher than healthcare peers (22.8x) and the fair ratio (34.7x). This makes shares look expensive if future growth falls short. Could momentum outpace value?
